RANI - Rani Therapeutics Holdings Inc logo

Rani Therapeutics Holdings Inc

RANI

Rani Therapeutics develops the RaniPill capsule, an oral delivery platform for biologics, offering alternatives to injections. Its pipeline includes treatments for rheumatoid arthritis, obesity, rare diseases, and inflammatory conditions in collaboration with partners.

⚕️ Healthcare NASDAQ Listed 2021 $ USD
$1,000 invested 5 years ago →$46today

Score Overview

1 Year
Score
Net Growth0.78%
Net TrendGrew
Net Income Consistency—
Rev Growth94.06%
Rev TrendGrew
Revenue Consistency—
5 Years
Score4.0
Net Growth-253.40%
Net Trend60%
Net Income Consistency—
Rev Growth16.64%
Rev Trend60%
Revenue Consistency—
All Time
Score
Net Growth-253.40%
Net Trend60%
Net Income Consistency
Rev Growth16.64%
Rev Trend60%
Revenue Consistency

Explore the 2021 public Archive ranking →

Where Rani Therapeutics Holdings Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 30 years of fundamentals. RANI does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-09-29
$ 0.80—
1 Year2025-09-29
$ 0.4963.33%
5 Years2021-09-29
$ 17.44-95.41%
All Time2021-07-30
$ 11.00-92.72%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 3M-$ 29M$ 43M
2025$ 1M-$ 29M$ 49M
2024$ 1M-$ 30M$ 27M
2023$ 0.00-$ 33M$ 48M
2022$ 0.00-$ 30M$ 98M
IPO2021$ 2M-$ 8M$ 117M
RANI - Rani Therapeutics Holdings Inc logo

Rani Therapeutics Holdings Inc fundamental performance

Between 2021 and 2025, revenue declined from $ 2M to $ 1M and net income went from -$ 8M to -$ 29M. Revenue increased in 60% of the years measured; net income in 60%.

Rani Therapeutics Holdings Inc currently holds a 5-year HDB Score of 4.0 out of 10. How the HDB Score is calculated.

Membership

Explore RANI with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,814 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year · Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies